MLN 8237 clinical trials
Also written Alisertib and MLN8237.
How each study uses MLN 8237 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MLN 8237 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
59 studies that test it; most in 2013 (13)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 8 |
| 2013 | 13 |
| 2014 | 6 |
| 2015 | 8 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2024 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 24 · Other 35
Millennium Pharmaceuticals, Inc. (20) · National Cancer Institute (NCI) (7) · Mayo Clinic (3) · M.D. Anderson Cancer Center (3) · Puma Biotechnology, Inc. (3) · Sidney Kimmel Cancer Center at Thomas Jefferson University (2) · Children's Oncology Group (2) · Massachusetts General Hospital (2)
Often tested with
Tested in the same studies.
Sapanisertib (1) · Romidepsin (1) · Cetuximab (1) · Rituximab (1) · Paclitaxel (1) · Hormone Therapy (1) · TAK 733 (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test MLN 8237.
- Oct 2027A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerPhase 2 · Puma Biotechnology, Inc.
Studies
Open first, then newest update. How each study uses MLN 8237 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 59
- A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)RecruitingPhase 2Puma Biotechnology, Inc.NCT07465757Written as Alisertib
- Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast CancerNot yet recruitingPhase 2University of Wisconsin, MadisonNCT07706179Written as Alisertib
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerRecruitingPhase 2Puma Biotechnology, Inc.NCT06369285Written as Alisertib
- A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerRecruitingPhase 2Puma Biotechnology, Inc.NCT06095505Written as Alisertib
- Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin LymphomaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01695941Written as Alisertib
- Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast CancerCompletedPhase 2Mayo ClinicNCT02860000Written as Alisertib
- Phase 2 Study of Alisertib Therapy for Rhabdoid TumorsActive, not recruitingPhase 2St. Jude Children's Research HospitalNCT02114229Written as alisertib
- Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung CancerCompletedPhase 1Collin BlakelyNCT04085315Written as Alisertib
- Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT04479306Written as Alisertib
- Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerCompletedPhase 1/2M.D. Anderson Cancer CenterNCT04555837Written as Alisertib
- Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate CancerCompletedPhase 1/2Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT01848067Written as Alisertib
- Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade GliomasCompletedPhase 1Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT02186509Written as Alisertib
- Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast CancerCompletedPhase 2US Oncology ResearchNCT02187991Written as Alisertib
- Phase II Trial of Alisertib (MLN8237) in Salvage Malignant MesotheliomaCompletedPhase 2M.D. Anderson Cancer CenterNCT02293005Written as Alisertib
- Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic CancerCompletedPhase 1Edward KimNCT01924260Written as alisertib
- MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal CarcinomaCompletedPhase 2Millennium Pharmaceuticals, Inc.NCT00853307Written as Alisertib
- Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic LeukemiaStatus unknownNot applicableNorthwestern UniversityNCT02530619Written as Alisertib
- Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedPhase 2Children's Oncology GroupNCT01154816Written as Alisertib
- Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AMLCompletedPhase 2Massachusetts General HospitalNCT02560025Written as Alisertib
- A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory LymphomaCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT02259010Written as Alisertib
See all 59 studies that test MLN 8237 →
Given beside what is tested · 5 — MLN 8237 is usual care or a partner of the new treatment
- Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast CancerCompletedPhase 1University of Colorado, DenverNCT02719691Written as Alisertib
- A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic MalignanciesCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT02327169Written as Alisertib
- MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal AdenocarcinomaTerminatedPhase 1Millennium Pharmaceuticals, Inc.NCT02551055Written as Alisertib
- Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast CancerCompletedPhase 2Millennium Pharmaceuticals, Inc.NCT01091428Written as Alisertib
- Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated MalignanciesWithdrawnPhase 1M.D. Anderson Cancer CenterNCT02812056Written as Alisertib